AFC
LENZ

Ares Financial Consulting’s LENZ Therapeutics LENZ Stock Holding History

Ares Financial Consulting’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108 Hold
19
– – ﹤0.01% 1121
2026
Q1 		$178 Hold
19
– – ﹤0.01% 1047
2025
Q4 		$304 Buy
+19
New +$554 ﹤0.01% 870

Other funds holding LENZ

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Ares Financial Consulting's LENZ Position: Q2 2026 in Review

Ares Financial Consulting held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 19 shares worth $108. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

Ares Financial Consulting first reported a position in LENZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $304 in Q4 2025. 25 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Ares Financial Consulting held 19 shares of LENZ Therapeutics worth $108 as of Q2 2026.
  • Ares Financial Consulting left its LENZ Therapeutics share count unchanged in Q2 2026.
  • LENZ Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1121 holding.
  • Ares Financial Consulting first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Ares Financial Consulting's LENZ Therapeutics position peaked at $304 in Q4 2025.
  • 25 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.